IFPMA 2016 interview series on ‘@ preICDRA2016 – What to expect?’
As regulatory stakeholders from around the world meet at the 17th International Conference of Drug Regulatory Authorities (ICDRA) in Cape Town, South Africa from 27 November to 2 December 2016 (http://www.icdra.co.za/), an open #preICDRA2016 conference, titled “Patients Are Waiting: How Regulators Collectively Make a Difference” will be convened from the 27-28 November 2016 at the International Convention Centre (ICC) in Cape Town. Experts from IFPMA’s regulatory groups will be actively involved at Pre-ICDRA as speakers on important related sessions, such as the way forward for life-cycle management; stakeholders’ collaboration in emergency situations and others. IFPMA & IPASA will also co-organize a special event on November 26. For more, click here
About IFPMA
IFPMA represents the innovative pharmaceutical industry at the international level, engaging in official relations with the United Nations and multilateral organizations. Our vision is to ensure that scientific progress translates into the next generation of medicines and vaccines that deliver a healthier future for people everywhere.
ifpma.org
To achieve this, we act as a trusted partner, bringing our members' expertise to champion pharmaceutical innovation, drive policy that supports the research, development, and delivery of health technologies, and create sustainable solutions that advance global health.
Related news and resources
IFPMA-INTERFARMA-FIFARMA statement on the Rio de Janeiro Declaration of the G20 Health Ministers
The innovative pharmaceutical industry, represented by IFPMA, INTERFARMA and FIFARMA reiterates its commitment to the G20 health priorities, reaffirmed in the Rio de Janeiro Declaration.
Read moreWHO EMRO RC71: Regional flagship initiative 1: Expanding equitable access to medical products
On 14 October 2024 in Doha, Qatar, IFPMA delivered a statement at the 71st session of the WHO EMRO Regional Committee on the Regional flagship initiative 1: Expanding equitable access to medical products.
Read moreThe Value of Reference Agency Assessment Reports in Enabling Regulatory Reliance
Access to information, including the assessment documents of reference national regulatory agencies (NRA), is a key enabler of regulatory risk-based decision making. It promotes an understanding of what was reviewed by the reference NRA, provides a rationale for decision making and promotes confidence and trust. The Centre for Innovation in Regulatory Science (CIRS) has published...
Read more